NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Prime Medicine, Inc. PRME
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.6M
▲ 55.3% vs FY2024
EPS · FY25
$-1.35
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-146.8%
Net margin · FY25
-4342.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.6M
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 4342 cents on every revenue dollar this year.
Per share
USD -1.35
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-146.8%
Return on equity, FY2025
ROE
Operating margin-4498.1%
Net margin-4342.4%
Return on assets-62.8%
Each USD of equity lost 147 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−2.3% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−2.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.18B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 342.7M
total assets, end of FY2025
Total assetsUSD 342.7M
EquityUSD 120.9M
CashUSD 63.0M
Current ratio4.84×
Equity funds 35% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
EBITDA $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
−0.0
−0.0
−0.0
0.0
Net income $B
−0.2
−0.2
−0.2
−0.1
−0.2
−0.0
EPS, diluted $
−1.35
−1.65
−2.18
−4.19
−14.19
−1.91
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−146.8
−136.9
−88.2
−152.2
·
−145.9
Shares out B
0.18
0.13
0.10
0.10
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
16 of 16
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed